SCHEMBL6899719

SCHEMBL6899719

CCCCCCCCCCCCCCCCC(=O)C(N)=O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.77
CES2 O00748 5/20 0.71
CES1 P23141 5/20 0.71
GPR84 Q9NQS5 7/20 0.54
PPARG P37231 6/20 0.54
PPARD Q03181 6/20 0.54
PPARA Q07869 6/20 0.54
HDAC11 Q96DB2 5/20 0.54
TSHR P16473 4/20 0.54
ALDH1A1 P00352 2/20 0.54
TLR2 O60603 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
FABP4 P15090 2/20 0.54
PTPN1 P18031 2/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
SLC22A8 Q8TCC7 1/20 0.54
MEN1 O00255 1/20 0.54
ESR1 P03372 1/20 0.54
ALOX15 P16050 1/20 0.54
PDE4A P27815 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16915217 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL5083248 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL28767487 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL8458168 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL29287856 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL3950801 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL6344027 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL5126810 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL609881 1.00 FAAH (0.77) FAAHCES2CES1GPR84PPARG
SCHEMBL1367098 0.97 FAAH (0.73) FAAHCES2CES1GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001035939-A2 OLEAMIDE IN EPILEPSY UNIVERSITY OF SUNDERLAND (GB) 2001-05-25 WO claimed
US-11345655-B2 Pseudoceramide compound and skin external composition comprising the same NEOPHARM CO., LTD. (KR) 2022-05-31 US disclosed
US-20180214472-A1 CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS VYOME BIOSCIENCES, PVT. LTD. (IN) 2018-08-02 US disclosed
US-9907812-B2 Conjugate-based antifungal and antibacterial prodrugs VYOME BIOSCIENCES PVT. LTD. (IN) 2018-03-06 US disclosed
US-20140364595-A1 CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS VYOME BIOSCIENCES (IN) 2014-12-11 US disclosed
EP-2723452-A2 CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS Vyome Biosciences Pvt Ltd (IN) 2014-04-30 EP disclosed
WO-2012177986-A2 CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS VYOME BIOSCIENCES (IN) 2012-12-27 WO disclosed
EP-0910561-B1 INHIBITORS OF OLEAMIDE HYDROLASE SCRIPPS RESEARCH INST (US) 2004-04-07 EP disclosed
WO-2001035939-A2 OLEAMIDE IN EPILEPSY UNIVERSITY OF SUNDERLAND (GB) 2001-05-25 WO disclosed
US-6096784-A Inhibitors of oleamide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2000-08-01 US disclosed
EP-0910561-A4 INHIBITORS OF OLEAMIDE HYDROLASE SCRIPPS RESEARCH INST (US) 2000-06-07 EP disclosed
EP-0910561-A1 INHIBITORS OF OLEAMIDE HYDROLASE The Scripps Research Institute (US) 1999-04-28 EP disclosed
US-5856537-A Inhibitors of oleamide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 1999-01-05 US disclosed
WO-1997049667-A1 INHIBITORS OF OLEAMIDE HYDROLASE THE SCRIPPS RESEARCH INSTITUTE (US) 1997-12-31 WO disclosed
US-4234464-A Detergent bar composition and binder therefor GAF CORPORATION (US) 1980-11-18 US disclosed
WO-1980002154-A1 DETERGENT BAR COMPOSITION AND BINDER THEREFOR GAF CORP (US) 1980-10-16 WO disclosed
US-4161491-A Process for the production of alpha-ketocarboxylic acid amides and cycloaliphatic products DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) 1979-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214472-A1 CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS XPO1, UGT1A1, UGT1A10 FAAH 2820/4885CES2 1161/4885CES1 680/4885
US-11345655-B2 Pseudoceramide compound and skin external composition comprising the same ASAH2, CERS2, CUTA FAAH 81/4885CES2 930/4885CES1 529/4885
US-20140364595-A1 CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS XPO1, MTX1, FUT5 FAAH 2175/4885CES2 1327/4885CES1 689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.